Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


SCCA Breast Cancer Clinical Trials

F-18 FES PET in Measuring Hormone Expression (7184)
Serial [F-18] fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy
Status Conditions Phase Study ID
Recruiting Breast Cancer N/A 7184
NCT02149173
Summary

This clinical trial studies F-18 16 alpha-fluoroestradiol (F-18 FES) positron emission tomography (PET) in measuring hormone expression in patients with recurrent or metastatic breast cancer undergoing endocrine-targeted therapy. Comparing results of diagnostic procedures done before, during, and after hormone therapy may help measure a patient's response to treatment.


Investigator
Hannah Linden, MD
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Adult, non-pregnant patients with biopsy-proven or clinically obvious primary, recurrent or metastatic breast cancer
  • Breast cancer from ER+ primary that is seen on other imaging tests; tumor ER expression must have been confirmed by immunohistocytochemistry of primary tumor or recurrent disease
  • At least one site of disease 1.5 cm or greater is needed to meet the spatial resolution limits of PET imaging
  • Patients must have been off tamoxifen or other estrogen receptor blocking agents for at least 6 weeks and off chemotherapy for 3 weeks for the initial baseline FES
  • Patients must be selected for an endocrine targeted therapy regimen for treatment of their breast cancer by the referring oncologist; selected treatments may be part of experimental treatment protocols for which the patient would be separately consented
  • Patients must be willing to undergo serial imaging procedures
  • Patients must agree to allow access to clinical records regarding response to treatment and long term follow up
Exclusions (conditions that would prevent participation in this study)
  • An inability to lie still for the tests
  • Individuals weighing more than 300 lb; (this is the weight limit of the scanner table)
  • Pregnant or lactating; women of childbearing potential with either a positive or no pregnancy test at baseline are excluded
  • Any other life-threatening illness (e.g. serious, uncontrolled concurrent infection or clinically significant cardiac disease - congestive heart failure, symptomatic coronary artery disease, cardiac arrhythmia not well controlled with medication)
  • Use of tamoxifen, Faslodex, diethylstilbestrol (DES) or any other ER blocking agent < 6 weeks or chemotherapy < 3 weeks prior to imaging scan
  • Unwillingness or inability to give informed consent
  • Uncontrolled diabetes mellitus (fasting glucose > 200 mg/dL)
  • Adult patients who require monitored anesthesia for PET scanning
Last Updated
June 11, 2014
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.